What the Options Market Tells Us About Amgen
What the Options Market Tells Us About Amgen
From the overall spotted trades, 4 are puts, for a total amount of $232,384 and 6, calls, for a total amount of $241,377.Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen.
有很多資金的大戶鯨魚明顯持有看好安進的立場。
Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.
查看安進（NASDAQ:AMGN）期權歷史，我們檢測到10筆交易。
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 40% with bearish.
如果我們考慮每個交易的具體情況，準確地說有40%的投資者持看漲期權，40%持看跌期權。
From the overall spotted trades, 4 are puts, for a total amount of $232,384 and 6, calls, for a total amount of $241,377.
從整體交易情況來看，有4筆看跌交易，總金額爲$232,384，有6筆看漲交易，總金額爲$241,377。
Projected Price Targets
預計價格目標
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $340.0 for Amgen over the last 3 months.
考慮到這些合約的成交量和持倉量，過去3個月來鯨魚們一直在以280.0到340.0美元的價格區間內瞄準Amgen。
Insights into Volume & Open Interest
成交量和持倉量分析
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
這些數據可以幫助您跟蹤Coinbase Glb期權的流動性和利益，以給定的行權價格爲基礎。
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
這些數據可以幫助您跟蹤給定行權價格的安進期權的流動性和興趣。
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $280.0 to $340.0 in the last 30 days.
下面，我們可以觀察過去30天內，安進所有看漲和看跌期權的成交量和持倉量的演變，分別在280.0美元至340.0美元的行權價範圍內。
Amgen Call and Put Volume: 30-Day Overview
安進看漲和看跌成交量：30天概述
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $5.3 | $4.7 | $4.7 | $330.00 | $133.9K | 462 | 330 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $24.45 | $23.55 | $24.35 | $340.00 | $61.0K | 1.2K | 51 |
| AMGN | CALL | TRADE | BEARISH | 10/18/24 | $60.35 | $58.75 | $58.75 | $280.00 | $41.1K | 82 | 7 |
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $27.45 | $26.6 | $26.6 | $330.00 | $39.9K | 1.1K | 1 |
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $26.75 | $26.35 | $26.35 | $330.00 | $39.5K | 1.1K | 43 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $5.3 | $4.7 | $4.7 | $330.00 | $133.9K | 462 | 330 |
| AMGN | 看漲 | SWEEP | 看好 | 01/17/25 | $24.45 | $23.55 | $24.35 | $340.00 | $61.0K | 1.2K | 51 |
| AMGN | 看漲 | 交易 | 看淡 | 10/18/24 | $60.35 | $58.75 | $58.75 | $280.00 | $41.1K | 82 | 7 |
| AMGN | 看漲 | SWEEP | 看淡 | 12/20/24 | $27.45 | $26.6 | $26.6 | $330.00 | $39.9千 | 1.1千 | 1 |
| AMGN | 看漲 | SWEEP | 看淡 | 12/20/24 | 26.75美元 | $26.35 | $26.35 | $330.00 | $39.5千 | 1.1千 | 43 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考慮到安進近期期權的歷史，現在適當關注該公司本身。我們旨在探討其當前業績。
Where Is Amgen Standing Right Now?
目前安進的處境如何？
- With a trading volume of 158,874, the price of AMGN is down by -0.24%, reaching $336.58.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 36 days from now.
- 安進的成交量爲158,874，價格下跌-0.24%，達到336.58美元。
- 當前RSI值表明該股票可能接近超買狀態。
- 下一個盈利報告將於36天后發佈。
Turn $1000 into $1270 in just 20 days?
在短短20天內，將1000美元變成1270美元？
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
20年期的專業期權交易員揭示了他的單線圖技巧，可以顯示何時買入和賣出。複製他的交易，每20天平均盈利27%。點擊這裏獲取更多信息。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。
